Pharmaceutical News

Covidien:           WHO: Jeffrey Saver, MD SWIFT, Lead Author ...

Physicians request Solitaire™ FR device for randomized, open-label multi-center study MANSFIELD, Mass.--(BUSINESS WIRE)--Jan. 30, 2012-- Covidien (NYSE:COV), a leading global provider of healthcare products, today announced that the Solitaire™ FR Revascularization Device has been approved for investigational use in the Interventional Management of Stroke (IMS III) trial. The Solitaire FR device was approved by the IMS III Executive Committee in the thrombectomy arm of the trial and was included in a recently approved amendment submitted to the U.S. Food and Drug Administration (FDA). The IMS III ...

View PDF Net sales up 5%; Medical Devices sales up 6% First-quarter diluted GAAP earnings per share from continuing operations were $1.02; excluding specified items, adjusted diluted earnings per share from continuing operations were $1.13, up 19% Fiscal 2012 sales guidance updated DUBLIN--(BUSINESS WIRE)--Jan. 26, 2012-- Covidien plc (NYSE: COV) today reported results for the first quarter of fiscal 2012 (October-December 2011). First-quarter net sales of $2.90 billion increased 5% from the $2.77 billion reported a year ago. Foreign exchange rate movement had no impact on the quarterly sales growth rate. First-quarter 2012 gross margin of 58.7% rose 2.0 percentage points fr...

MIAMI--(BUSINESS WIRE)--Jan. 24, 2012-- Covidien (NYSE: COV), a leading global provider of healthcare products, today announced that one-year results on the use of its EverFlex™ stent for superficial femoral artery stenting were presented here during the International Symposium on Endovascular Therapy (ISET) Conference. Presenting the data was co-National Principal Investigator Jon Matsumura, MD, of the Division of Vascular Surgery, University of Wisconsin School of Medicine and Public Health, Madison, Wisconsin. Named DURABILITY II, the clinical study enrolled 287 subjects at 44 investigational sites in both the U.S....

Final Results from DEFINITIVE Ca++ Clinical Study Presented at ISET 2012 MIAMI--(BUSINESS WIRE)--Jan. 23, 2012-- Covidien (NYSE:COV), a leading global provider of healthcare products, today released the results of the DEFINITIVE Ca++ study. DEFINITIVE Ca++ assessed the safety and effectiveness of the SilverHawk™ LS-C/TurboHawk™ Peripheral Plaque Excision Systems when used in conjunction with the SpiderFX™ Embolic Protection System to treat moderate to severely calcified lesions in the femoropopliteal artery. These calcified lesions are a form of Peripheral Arterial Disease (P.A.D.). The study was...

MANSFIELD, Mass.--(BUSINESS WIRE)--Jan. 23, 2012-- Covidien (NYSE: COV), a leading global supplier of healthcare products, today announced that Stacy Enxing Seng has been appointed President of the Company’s Vascular Therapies Global Business Unit. She will report directly to Peter L. Wehrly, Senior Vice President and Group President, Respiratory & Monitoring Solutions and Vascular Therapies. Enxing Seng, 47, will be responsible for managing a global organization of 4,000 employees with $1.4 billion in revenue. She joined Covidien in July 2010 through the ev3 acquisition, where she was a founding member and execut...

CEO and President José E. Almeida Assumes Additional Duties DUBLIN--(BUSINESS WIRE)--Jan. 20, 2012-- Covidien plc (NYSE: COV) today announced that its Board of Directors has elected President and Chief Executive Officer José E. Almeida to the additional position of Chairman of the Board, effective March 13, 2012. Jose E. Almeida, Covidien plc (Photo: Business Wire) Mr. Almeida will succeed Richard J. Meelia, who has served as Chairman since October 2008. Mr. Meelia agreed to serve as Non-Executive Chairman of the Board for a transition period of up to one year following his July 2011 retirement as...

DUBLIN--(BUSINESS WIRE)--Jan. 19, 2012-- Covidien plc (NYSE: COV) today announced that its Board of Directors has declared a quarterly cash dividend of $0.225 per ordinary share. The dividend is payable on February 22, 2012, to shareholders of record on January 30, 2012. ABOUT COVIDIEN Covidien is a leading global healthcare products company that creates innovative medical solutions for better patient outcomes and delivers value through clinical leadership and excellence. Covidien manufactures, distributes and services a diverse range of industry-leading product lines in three segments: Medical Devices,...

BOULDER, Colo., Jan 19, 2012 (BUSINESS WIRE) --On November 8, 2011, Covidien initiated a voluntary recall of certain lots of its BIS(TM) Bilateral Sensors, due to a modification which inadvertently reversed the reference and left eye electrode. This modification could potentially cause a change in the performance of BIS monitoring systems when these sensors are used, resulting in the inaccurate calculation and presentation of processed EEG information for Bispectral Index(TM) (BIS), Density Spectral Array (DSA), and Asymmetry (ASYM) values. To date, there have been no reports of patient injury related to the recalled products...

BOULDER, Colo.--(BUSINESS WIRE)--Jan. 19, 2012-- On November 8, 2011, Covidien initiated a voluntary recall of certain lots of its BIS™ Bilateral Sensors, due to a modification which inadvertently reversed the reference and left eye electrode. This modification could potentially cause a change in the performance of BIS monitoring systems when these sensors are used, resulting in the inaccurate calculation and presentation of processed EEG information for Bispectral Index™ (BIS), Density Spectral Array (DSA), and Asymmetry (ASYM) values. To date, there have been no reports of patient injury related to the recall...